
  
    
      
        Background_NNP
        New_JJ antiretroviral_NN therapies_NNS introduced_VBN in_IN the_DT mid_JJ 1990_CD s_VBZ
        have_VBP allowed_VBN many_JJ persons_NNS with_IN HIV_NNP infection_NN to_TO live_VB longer_RBR
        before_IN progressing_VBG to_TO AIDS_NNP ,_, and_CC to_TO have_VB longer_JJR survival_NN
        following_VBG an_DT AIDS_NNP diagnosis_NN [_NN 1_CD 2_CD 3_CD ]_NN ._. The_DT annual_JJ number_NN
        of_IN deaths_NNS due_JJ to_TO AIDS_NNP in_IN the_DT United_NNP States_NNPS peaked_VBD in_IN 1995_CD
        and_CC has_VBZ since_IN declined_VBN [_NN 4_CD ]_NN ,_, resulting_VBG in_IN an_DT increase_NN in_IN
        the_DT number_NN of_IN prevalent_JJ AIDS_NNP cases_NNS ._. Current_JJ clinical_JJ
        guidelines_NNS [_NN 5_CD ]_NN call_NN for_IN persons_NNS infected_VBN with_IN HIV_NNP to_TO take_VB
        a_DT combination_NN of_IN antiretroviral_NN medications_NNS to_TO decrease_VB
        viral_JJ load_NN ,_, maintain_VB immune_JJ cell_NN function_NN ,_, and_CC prevent_VB the_DT
        development_NN of_IN resistant_JJ viral_JJ strains_NNS ._. Thus_RB ,_, for_IN many_JJ
        patients_NNS the_DT treatment_NN of_IN HIV_NNP has_VBZ evolved_VBN more_JJR toward_IN a_DT
        model_NN of_IN chronic_JJ disease_NN management_NN ,_, with_IN patients_NNS taking_VBG a_DT
        variety_NN of_IN potent_JJ medications_NNS for_IN extended_VBN periods_NNS of_IN
        time_NN ._.
        Besides_IN clinical_JJ outcomes_NNS ,_, health-related_JJ quality_NN of_IN
        life_NN (_( HRQOL_NNP )_) and_CC disability_NN are_VBP important_JJ issues_NNS for_IN
        persons_NNS treated_VBN for_IN chronic_JJ diseases_NNS [_NN 6_CD 7_CD 8_CD 9_CD 10_CD 11_CD ]_NN ,_,
        including_VBG HIV_NNP infection_NN [_NN 12_CD 13_CD 14_CD ]_NN ._. Populations_NNP with_IN HIV_NNP
        infection_NN or_CC AIDS_NNP have_VBP reported_VBN different_JJ levels_NNS of_IN HRQOL_NNP ,_,
        both_DT in_IN clinical_JJ trials_NNS [_NN 15_CD 16_CD 17_CD 18_CD ]_NN and_CC
        population-based_JJ research_NN [_NN 19_CD 20_CD 21_CD ]_NN ._. We_PRP present_JJ summary_NN
        information_NN from_IN a_DT multi-site_JJ supplemental_JJ surveillance_NN
        project_NN that_WDT describes_VBZ the_DT levels_NNS of_IN HRQOL_NNP reported_VBN by_IN
        HIV-infected_NNP persons_NNS in_IN different_JJ demographic_JJ and_CC
        behavioral_JJ risk_NN factor_NN groups_NNS ,_, stressing_VBG the_DT relationship_NN
        between_IN disease_NN progression_NN and_CC HRQOL_NNP ._.
      
      
        Methods_NNP
        Since_IN 1990_CD ,_, the_DT Centers_NNPS for_IN Disease_NNP Control_NNP and_CC
        Prevention_NNP (_( CDC_NNP )_) has_VBZ conducted_VBN the_DT Supplement_NNP to_TO HIV_NNP /_NN AIDS_NNP
        Surveillance_NNP (_( SHAS_NNP )_) Project_NN ,_, an_DT ongoing_JJ cross-sectional_JJ
        interview_NN study_NN designed_VBN to_TO collect_VB supplemental_JJ behavioral_JJ
        surveillance_NN data_NNS from_IN persons_NNS with_IN HIV_NNP infection_NN [_NN 22_CD ]_NN ._.
        Persons_NNP 18_CD years_NNS of_IN age_NN or_CC older_JJR reported_VBD with_IN HIV_NNP or_CC AIDS_NNP
        through_IN routine_JJ case_NN surveillance_NN were_VBD eligible_JJ for_IN
        participation_NN ._. Participants_NNS were_VBD enrolled_VBN using_VBG one_CD of_IN
        three_CD methods_NNS :_: (_( 1_LS )_) facility-based_JJ recruitment_NN of_IN all_DT
        eligible_JJ persons_NNS seeking_VBG treatment_NN at_IN selected_VBN health_NN care_NN
        facilities_NNS in_IN Atlanta_NNP ,_, Connecticut_NNP ,_, Denver_NNP ,_, Detroit_NNP ,_,
        Florida_NNP ,_, and_CC New_NNP Jersey_NNP ;_: (_( 2_LS )_) population-based_JJ recruitment_NN
        of_IN all_DT eligible_JJ persons_NNS in_IN Arizona_NNP ,_, Delaware_NNP ,_, New_NNP Mexico_NNP
        and_CC South_NNP Carolina_NNP ;_: and_CC (_( 3_LS )_) population-based_JJ recruitment_NN of_IN
        a_DT 30_CD %_NN sample_NN of_IN men_NNS who_WP have_VBP sex_NN with_IN men_NNS (_( MSM_NNP )_) and_CC 100_CD %_NN of_IN
        all_DT other_JJ eligible_JJ persons_NNS in_IN Washington_NNP State_NNP and_CC Los_NNP
        Angeles_NNP County_NNP ,_, California_NNP ._. During_IN the_DT period_NN examined_VBD for_IN
        this_DT analysis_NN ,_, Arizona_NNP ,_, Denver_NNP ,_, Detroit_NNP ,_, New_NNP Jersey_NNP ,_, and_CC
        South_NNP Carolina_NNP interviewed_VBD persons_NNS with_IN HIV_NNP infection_NN in_IN
        addition_NN to_TO those_DT with_IN AIDS_NNP ._. (_( Three_CD sites-_NN Detroit_NNP ,_, South_NNP
        Carolina_NNP ,_, and_CC Washington-opted_NNP not_RB to_TO collect_VB data_NNS using_VBG
        the_DT HRQOL_NNP module_NN and_CC were_VBD excluded_VBN from_IN all_DT analyses_NNS ._. )_)
        Informed_NNP consent_NN was_VBD obtained_VBN from_IN all_DT participants_NNS prior_RB
        to_TO the_DT interview_NN ,_, and_CC the_DT study_NN has_VBZ received_VBN institutional_JJ
        review_NN board_NN approval_NN at_IN both_DT the_DT CDC_NNP and_CC local_JJ levels_NNS ._.
        Trained_VBN interviewers_NNS conducted_VBD a_DT standardized_JJ interview_NN in_IN
        either_DT English_NNP or_CC Spanish_JJ that_WDT includes_VBZ questions_NNS on_IN
        demographic_JJ characteristics_NNS ,_, drug_NN and_CC alcohol_NN use_NN ,_, sexual_JJ
        behaviors_NNS ,_, and_CC medical_JJ and_CC social_JJ service_NN information_NN ._. Data_NNP
        are_VBP self-reported_JJ and_CC are_VBP not_RB verified_VBN through_IN medical_JJ
        record_NN review_NN or_CC clinical_JJ tests_NNS ._. On_IN average_JJ interviews_NNS take_VBP
        approximately_RB 45_CD minutes_NNS to_TO complete_VB ._. Data_NNP were_VBD sent_VBN to_TO CDC_NNP
        without_IN any_DT personal_JJ identifying_VBG information_NN ._.
        The_DT format_NN of_IN the_DT SHAS_NNP Project_NNP allows_VBZ the_DT questionnaire_NN
        to_TO be_VB modified_VBN to_TO collect_VB data_NNS on_IN additional_JJ topics_NNS of_IN
        interest_NN ._. From_IN January_NNP 1995_CD through_IN December_NNP 1996_CD ,_, a_DT module_NN
        of_IN questions_NNS adapted_VBN from_IN research_NN conducted_VBN by_IN Albert_NNP Wu_NNP
        and_CC colleagues_NNS [_NN 23_CD ]_NN was_VBD added_VBN to_TO study_VB the_DT levels_NNS of_IN
        self-reported_JJ HRQOL_NNP ._. Wu_NNP et_CC al_NN compiled_VBN questions_NNS from_IN the_DT
        RAND_NNP Medical_NNP Outcomes_NNP Study_NNP (_( MOS_NNP )_) [_NN 24_CD ]_NN as_RB well_RB as_IN
        additional_JJ items_NNS to_TO measure_VB other_JJ dimensions_NNS of_IN health_NN
        (_( energy_NN ,_, distress_NN ,_, and_CC cognitive_JJ function_NN )_) potentially_RB
        relevant_JJ to_TO HIV_NNP disease_NN ._. Wu_NNP et_CC al_NN found_VBD that_IN their_PRP$ modified_VBN
        health_NN status_NN questionnaire_NN reliably_RB and_CC distinctly_RB
        measured_VBN aspects_NNS of_IN health_NN among_IN HIV-positive_NNP persons_NNS
        recruited_VBN for_IN two_CD clinical_JJ trials_NNS of_IN zidovudine_NN ._.
        HIV-infected_NNP persons_NNS who_WP were_VBD asymptomatic_JJ had_VBD higher_JJR
        scores_NNS on_IN most_JJS HRQOL_NNP dimensions-indicating_JJ relatively_RB less_JJR
        disability_NN and_CC a_DT better_JJR quality_NN of_IN life-than_JJ persons_NNS who_WP
        were_VBD diagnosed_VBN with_IN early_JJ AIDS_NNP related_VBD complex_JJ ._.
        The_DT SHAS_NNP Quality_NNP of_IN Life_NNP module_NN was_VBD used_VBN to_TO collect_VB
        information_NN on_IN self-reported_JJ HRQOL_NNP in_IN the_DT following_JJ
        dimensions_NNS :_: Overall_RB Health_NNP ,_, Pain_NNP ,_, Physical_NNP Functioning_NNP ,_,
        Role_NNP Functioning_NNP ,_, Social_NNP Functioning_NNP ,_, Mental_NNP Health_NNP ,_,
        Energy_NNP /_NN Fatigue_NNP ,_, and_CC Cognitive_NNP Functioning_NNP ._. These_DT eight_CD
        HRQOL_NNP dimensions_NNS were_VBD measured_VBN using_VBG 24_CD questions_NNS (_( a_DT subset_NN
        of_IN the_DT 30_CD MOS_NNP questions_NNS used_VBN by_IN Wu_NNP et_CC al_NN )_) ._. Response_NNP scores_NNS
        for_IN each_DT HRQOL_NNP dimension_NN were_VBD transformed_VBN linearly_RB on_IN scale_NN
        of_IN 0_CD to_TO 100_CD ._. Multi-item_NNP dimensions_NNS were_VBD scored_VBN by_IN summing_VBG
        item_NN responses_NNS ,_, and_CC internal_JJ consistency_NN coefficients_NNS
        (_( Cronbach_NNP 's_POS alpha_NN [_NN 25_CD ]_NN )_) were_VBD calculated_VBN ._. For_IN each_DT
        dimension_NN ,_, lower_JJR scores_NNS indicate_VBP relatively_RB lower_JJR
        self-perceived_JJ quality_NN of_IN life_NN for_IN that_DT health_NN measure_NN
        compared_VBN to_TO higher_JJR scores_NNS ._.
        Analysis_NNP of_IN variance_NN tests_NNS were_VBD used_VBN to_TO compare_VB crude_NN
        mean_NN HRQOL_NNP scores_NNS across_IN demographic_JJ and_CC behavioral_JJ
        categories_NNS ;_: because_IN the_DT sample_NN was_VBD large_JJ the_DT significance_NN
        level_NN for_IN univariate_NN analysis_NN was_VBD set_VBN at_IN P_NN <_NN 0_CD ._. 01_CD ._.
        Multivariate_NNP linear_JJ regression_NN (_( least-squares_JJ means_VBZ )_) was_VBD
        used_VBN to_TO identify_VB independent_JJ factors_NNS associated_VBN with_IN HRQOL_NNP
        in_IN the_DT statistical_JJ models_NNS ;_: analyses_NNS included_VBD variables_NNS
        noted_VBD from_IN the_DT literature_NN as_RB potentially_RB associated_VBN with_IN
        quality_NN of_IN life_NN (_( e_SYM ._. g_SYM ._. ,_, age_NN ,_, sex_NN ,_, education_NN ,_, and_CC income_NN )_) ._.
        Linear_NNP regression_NN models_NNS were_VBD then_RB constructed_VBN using_VBG the_DT
        separate_JJ HRQOL_NNP dimension_NN scores_NNS as_IN the_DT outcomes_NNS ;_: here_RB ,_, the_DT
        significance_NN level_NN was_VBD set_VBN at_IN P_NN <_NN 0_CD ._. 05_CD ._. Tukey-_NNP Kramer_NNP
        adjustments_NNS for_IN multiple_JJ comparisons_NNS were_VBD used_VBN where_WRB
        appropriate_JJ ._. Age_NNP and_CC education_NN were_VBD included_VBN in_IN the_DT models_NNS
        as_IN continuous_JJ predictor_NN variables_NNS ;_: CD_NNP 4_CD count_NN ,_, gender_NN ,_,
        income_NN ,_, race_NN /_NN ethnicity_NN ,_, mode_NN of_IN exposure_NN ,_, time_NN known_VBN to_TO be_VB
        HIV_NNP +_NN ,_, currently_RB taking_VBG antiretroviral_NN therapy_NN (_( yes_UH versus_CC
        no_DT )_) ,_, and_CC type_NN of_IN SHAS_NNP recruitment_NN (_( population-based_JJ versus_CC
        facility-based_JJ )_) were_VBD included_VBN as_IN categorical_JJ predictor_NN
        variables_NNS ._. To_TO simplify_VB comparisons_NNS across_IN HRQOL_NNP dimensions_NNS ,_,
        we_PRP report_VBP results_NNS for_IN models_NNS including_VBG all_DT predictor_NN
        variables_NNS ,_, regardless_RB of_IN whether_IN any_DT individual_JJ variable_NN
        was_VBD predictive_JJ of_IN the_DT outcome_NN ._. All_DT analyses_NNS were_VBD conducted_VBN
        using_VBG SAS_NNP Version_NNP 6_CD ._. 12_CD (_( SAS_NNP Institute_NNP ,_, Inc_NNP ._. ,_, Cary_NNP ,_, NC_NNP ,_,
        USA_NNP )_) ._.
      
      
        Results_NNS
        From_IN January_NNP 1995_CD through_IN December_NNP 1996_CD ,_, 6128_CD persons_NNS
        were_VBD identified_VBN for_IN interview_NN at_IN the_DT nine_CD sites_NNS that_WDT
        administered_VBN the_DT HRQOL_NNP module_NN ._. Of_IN these_DT ,_, 614_CD were_VBD found_VBN to_TO
        have_VB died_VBN before_IN they_PRP could_MD be_VB contacted_VBN ._. Of_IN the_DT remaining_VBG
        5514_CD ,_, 4246_CD (_( 77_CD ._. 0_CD %_NN )_) completed_VBN SHAS_NNP interviews_NNS ,_, 463_CD (_( 8_CD ._. 4_LS %_NN )_)
        refused_VBD to_TO participate_VB ,_, 394_CD (_( 7_CD ._. 1_LS %_NN )_) could_MD not_RB be_VB located_VBN ,_,
        and_CC 353_CD (_( 6_CD ._. 4_LS %_NN )_) were_VBD located_VBN but_CC were_VBD too_RB ill_JJ (_( either_CC
        physically_RB or_CC mentally_RB )_) to_TO participate_VB ._. Sites_NNP phased_VBD out_RP
        the_DT HRQOL_NNP module_NN at_IN various_JJ times_NNS during_IN the_DT two-year_JJ
        period_NN ;_: HRQOL_NNP data_NNS were_VBD available_JJ from_IN 3778_CD interviews_NNS ._.
        Persons_NNP administered_VBN the_DT HRQOL_NNP module_NN were_VBD demographically_RB
        similar_JJ to_TO persons_NNS who_WP did_VBD not_RB participate_VB in_IN SHAS_NNP
        (_( refused_VBD ,_, could_MD not_RB be_VB located_VBN ,_, or_CC too_RB ill_JJ )_) ,_, except_IN that_IN a_DT
        slightly_RB higher_JJR percentage_NN of_IN those_DT who_WP did_VBD not_RB participate_VB
        were_VBD male_JJ (_( 76_CD ._. 0_CD %_NN vs_NNS ._. 73_CD ._. 5_LS %_NN )_) and_CC white_JJ (_( 40_CD ._. 5_LS %_NN vs_NNS ._. 34_CD ._. 0_CD %_NN ;_:
        chi-square_JJ test_NN of_IN proportions_NNS ,_, P_NN <_NN 0_CD ._. 001_CD )_) ._.
        The_DT multi-item_JJ HRQOL_NNP dimensions_NNS of_IN Physical_NNP Functioning_NNP ,_,
        Role_NNP Functioning_NNP ,_, Mental_NNP Health_NNP ,_, Energy_NNP /_NN Fatigue_NNP ,_, and_CC
        Cognitive_NNP Functioning_NNP were_VBD internally_RB consistent_JJ in_IN our_PRP$
        sample_NN (_( Table_NNP 1_CD ;_: all_DT Cronbach_NNP 's_POS alpha_NN ≥_NN 0_CD ._. 84_CD )_) ._.
        Demographic_NNP characteristics_NNS of_IN the_DT HRQOL_NNP module_NN
        participants_NNS are_VBP shown_VBN in_IN Table_NNP 2_CD ._. The_DT median_JJ age_NN of_IN those_DT
        providing_VBG HRQOL_NNP information_NN was_VBD 37_CD years_NNS (_( range_NN :_: 18_CD -_: 84_CD )_) ._.
        AIDS_NNP had_VBD been_VBN diagnosed_VBN in_IN 81_CD ._. 1_LS %_NN of_IN participants_NNS ,_, 70_CD ._. 9_CD %_NN had_VBD
        known_VBN of_IN their_PRP$ HIV_NNP infection_NN for_IN 12_CD months_NNS or_CC more_JJR ,_, and_CC
        65_CD ._. 0_CD %_NN were_VBD currently_RB taking_VBG any_DT antiretroviral_NN medications_NNS
        (_( i_NNP ._. e_SYM ._. ,_, zidovudine_NN ,_, didanosine_NN ,_, zalcitabine_NN ,_, stavudine_NN ,_, or_CC
        experimental_JJ HIV_NNP drugs_NNS ,_, including_VBG protease_NN inhibitors_NNS )_) ._. The_DT
        population_NN mean_NN score_NN on_IN the_DT dimension_NN of_IN Overall_RB Health_NNP
        was_VBD 50_CD ._. 4_LS (_( on_IN a_DT scale_NN of_IN 0_CD to_TO 100_CD )_) ._.
        Mean_VB HRQOL_NNP scores_NNS were_VBD stratified_JJ across_IN demographic_JJ and_CC
        behavioral_JJ categories_NNS and_CC compared_VBN by_IN using_VBG the_DT analysis_NN of_IN
        variance_NN ._. As_IN seen_VBN in_IN Table_NNP 2_CD ,_, lower_JJR Overall_RB Health_NNP scores_NNS
        were_VBD associated_VBN with_IN older_JJR age_NN ,_, female_JJ sex_NN ,_, black_JJ or_CC
        Hispanic_JJ race_NN /_NN ethnicity_NN ,_, HIV_NNP exposure_NN through_IN injection_NN
        drug_NN use_NN ,_, lower_JJR CD_NNP 4_CD count_NN ,_, less_JJR than_IN 12_CD years_NNS of_IN education_NN ,_,
        no_DT private_JJ health_NN insurance_NN ,_, and_CC lower_JJR income_NN ._. Mean_VB scores_NNS
        for_IN each_DT of_IN the_DT remaining_VBG HRQOL_NNP dimensions_NNS were_VBD also_RB
        computed_JJ and_CC similarly_RB compared_VBN by_IN demographic_JJ
        characteristics_NNS ._. In_IN most_JJS instances_NNS in_IN which_WDT significant_JJ
        differences_NNS were_VBD found_VBN ,_, lower_JJR HRQOL_NNP was_VBD associated_VBN with_IN the_DT
        factors_NNS already_RB listed_VBN (_( data_NNS not_RB displayed_VBN )_) ._.
        In_IN linear_JJ regression_NN analyses_NNS ,_, lower_JJR CD_NNP 4_CD count_NN ,_, less_JJR
        education_NN ,_, lower_JJR income_NN ,_, and_CC older_JJR age_NN were_VBD consistently_RB
        associated_VBN with_IN lower_JJR HRQOL_NNP scores_NNS ._. Table_NNP 3_CD shows_VBZ the_DT HRQOL_NNP
        scores_NNS stratified_JJ by_IN CD_NNP 4_CD count_NN adjusted_VBN for_IN the_DT other_JJ
        predictor_NN variables_NNS ,_, using_VBG the_DT Least_NNP Squares_NNP Means_NNP
        technique_NN (_( the_DT group_NN labeled_VBN "_'' CD_NNP 4_CD Unknown_JJ "_'' includes_VBZ those_DT
        who_WP never_RB had_VBD a_DT CD_NNP 4_CD test_NN as_RB well_RB as_IN those_DT who_WP had_VBD a_DT CD_NNP 4_CD
        test_NN but_CC could_MD not_RB recall_VB the_DT result_NN )_) ._. On_IN all_DT but_CC two_CD of_IN
        the_DT HRQOL_NNP measures_NNS ,_, self-reported_JJ HRQOL_NNP decreased_VBD as_IN CD_NNP 4_CD
        count_NN decreased_VBD ._. CD_NNP 4_CD count_NN was_VBD not_RB associated_VBN with_IN the_DT
        measures_NNS of_IN Mental_NNP Health_NNP and_CC Cognitive_NNP Function_NNP ._.
        We_PRP were_VBD also_RB interested_JJ in_IN the_DT relationship_NN between_IN
        antiretroviral_NN therapy_NN and_CC HRQOL_NNP ._. Most_JJS of_IN the_DT study_NN
        population_NN (_( 65_CD ._. 0_CD %_NN )_) was_VBD currently_RB taking_VBG antiretroviral_NN
        medication_NN ._. Taking_VBG antiretroviral_NN medication_NN differed_VBD
        significantly_RB by_IN CD_NNP 4_CD count_NN :_: 75_CD ._. 1_LS %_NN of_IN those_DT with_IN a_DT CD_NNP 4_CD count_NN
        of_IN <_NN 200_CD were_VBD currently_RB taking_VBG antiretroviral_NN medication_NN ,_,
        compared_VBN to_TO 68_CD ._. 5_LS %_NN with_IN a_DT CD_NNP 4_CD count_NN of_IN 200_CD -_: 499_CD ,_, and_CC 27_CD ._. 3_LS %_NN
        with_IN a_DT CD_NNP 4_CD count_NN of_IN ≥_NN 500_CD (_( P_NN <_NN 0_CD ._. 001_CD ,_, Mantel_NNP Hantzel_NNP
        chi-square_JJ test_NN for_IN trend_NN )_) ._. In_IN univariate_NN analysis_NN ,_, current_JJ
        antiretroviral_NN therapy_NN was_VBD associated_VBN with_IN only_RB two_CD HRQOL_NNP
        dimensions_NNS :_: therapy_NN was_VBD negatively_RB associated_VBN with_IN Role_NNP
        Function_NNP and_CC positively_RB associated_VBN with_IN Mental_NNP Health_NNP ._. For_IN
        the_DT dimension_NN of_IN Role_NNP Function_NNP ,_, currently_RB taking_VBG
        antiretroviral_NN medication_NN was_VBD associated_VBN with_IN a_DT lower_JJR HRQOL_NNP
        score_NN (_( 44_CD ._. 3_LS )_) than_IN that_DT of_IN persons_NNS not_RB currently_RB taking_VBG
        medication_NN (_( 49_CD ._. 8_CD ;_: P_NN <_NN 0_CD ._. 001_CD )_) ._. However_RB ,_, in_IN the_DT
        multivariate_NN models_NNS examining_VBG HRQOL_NNP scores_NNS stratified_JJ by_IN
        CD_NNP 4_CD count_NN ,_, currently_RB taking_VBG antiretroviral_NN medication_NN was_VBD
        not_RB associated_VBN with_IN differences_NNS in_IN HRQOL_NNP ._.
      
      
        Discussion_NNP
        Disability_NNP and_CC health-related_JJ quality_NN of_IN life_NN are_VBP
        becoming_VBG increasingly_RB important_JJ issues_NNS associated_VBN with_IN HIV_NNP
        disease_NN ._. New_JJ developments_NNS in_IN the_DT treatment_NN of_IN HIV_NNP have_VBP
        produced_VBN dramatic_JJ improvements_NNS in_IN the_DT clinical_JJ and_CC
        immunologic_JJ health_NN for_IN many_JJ patients_NNS ,_, with_IN a_DT resulting_VBG
        reduction_NN in_IN deaths_NNS due_JJ to_TO AIDS_NNP in_IN the_DT United_NNP States_NNPS ._. Along_IN
        with_IN clinical_JJ indicators_NNS of_IN morbidity_NN and_CC mortality_NN ,_,
        measures_NNS of_IN HRQOL_NNP (_( such_JJ as_IN physical_JJ functioning_NN ,_, mental_JJ
        health_NN ,_, pain_NN ,_, and_CC energy_NN )_) can_MD help_VB guide_VB treatment_NN
        decisions_NNS for_IN both_DT patients_NNS and_CC providers_NNS ._.
        Like_IN other_JJ researchers_NNS ,_, we_PRP found_VBD that_IN lower_JJR HRQOL_NNP scores_NNS
        and_CC poorer_JJR perception_NN of_IN health_NN were_VBD associated_VBN with_IN more_JJR
        advanced_VBD disease_NN ._. A_DT majority_NN of_IN the_DT SHAS_NNP participants_NNS had_VBD
        an_DT AIDS_NNP diagnosis_NN at_IN the_DT time_NN of_IN their_PRP$ interview_NN ._. However_RB ,_,
        a_DT broad_JJ range_NN of_IN CD_NNP 4_CD levels_NNS is_VBZ represented_VBN in_IN the_DT study_NN
        population_NN ._. Both_DT facility-based_JJ and_CC population-based_JJ
        strategies_NNS were_VBD used_VBN to_TO recruit_VB SHAS_NNP participants_NNS ._. The_DT
        study_NN population_NN included_VBD large_JJ numbers_NNS of_IN women_NNS ,_,
        racial_JJ /_NN ethnic_JJ minorities_NNS ,_, and_CC persons_NNS infected_VBN with_IN HIV_NNP
        through_IN injection_NN drug_NN use_NN or_CC heterosexual_NN risk_NN ._. These_DT
        groups_NNS have_VBP not_RB been_VBN extensively_RB reported_VBN in_IN previous_JJ
        studies_NNS of_IN HIV_NNP and_CC HRQOL_NNP ,_, in_IN which_WDT the_DT populations_NNS have_VBP
        been_VBN more_JJR representative_NN of_IN white_JJ male_JJ clinic_NN patients_NNS [_NN 16_CD
        17_CD 18_CD 26_CD 27_CD 28_CD ]_NN ._. Where_WRB significant_JJ differences_NNS were_VBD found_VBN
        by_IN univariate_NN analysis_NN ,_, women_NNS ,_, blacks_NNS ,_, Hispanics_NNPS ,_, and_CC
        persons_NNS infected_VBN with_IN HIV_NNP through_IN injection_NN drug_NN use_NN had_VBD
        lower_JJR mean_NN HRQOL_NNP scores_NNS ._. However_RB ,_, in_IN multivariate_NN linear_JJ
        regression_NN ,_, sex_NN ,_, race_NN /_NN ethnicity_NN ,_, and_CC HIV_NNP infection_NN risk_NN
        were_VBD not_RB associated_VBN with_IN differences_NNS in_IN HRQOL_NNP when_WRB
        stratified_JJ by_IN CD_NNP 4_CD count_NN ._.
        Several_JJ limitations_NNS should_MD be_VB considered_VBN in_IN the_DT
        interpretation_NN of_IN our_PRP$ findings_NNS ._. SHAS_NNP is_VBZ a_DT cross-sectional_JJ
        interview_NN study_NN with_IN data_NNS self-reported_JJ by_IN the_DT participant_NN ._.
        Critical_JJ indicators_NNS of_IN disease_NN progression_NN ,_, such_JJ as_IN CD_NNP 4_CD
        count_NN ,_, were_VBD not_RB confirmed_VBN through_IN clinical_JJ testing_NN or_CC
        review_NN of_IN medical_JJ records_NNS ._. Among_IN those_DT who_WP reported_VBD having_VBG
        ever_RB had_VBD a_DT CD_NNP 4_CD count_NN ,_, 12_CD ._. 5_LS %_NN could_MD not_RB recall_VB the_DT most_RBS
        recent_JJ CD_NNP 4_CD count_NN ;_: on_IN most_JJS HRQOL_NNP dimensions_NNS their_PRP$ scores_NNS lay_VBP
        between_IN the_DT scores_NNS for_IN the_DT lowest_JJS and_CC middle_JJ CD_NNP 4_CD groups_NNS ._.
        This_DT finding_VBG suggests_VBZ they_PRP were_VBD more_JJR advanced_VBD in_IN their_PRP$ HIV_NNP
        disease_NN ;_: indeed_RB ,_, 83_CD ._. 6_CD %_NN were_VBD reported_VBN to_TO the_DT national_JJ
        surveillance_NN system_NN as_IN having_VBG AIDS_NNP ._. The_DT SHAS_NNP questionnaire_NN
        also_RB did_VBD not_RB adequately_RB capture_VB the_DT composition_NN of_IN a_DT
        person_NN 's_POS past_JJ and_CC current_JJ antiretroviral_NN therapies_NNS ,_, or_CC the_DT
        duration_NN of_IN ,_, and_CC adherence_NN to_TO ,_, those_DT therapies_NNS ._.
        Specifically_RB ,_, this_DT questionnaire_NN does_VBZ not_RB assess_VB the_DT
        effects_NNS of_IN protease_NN inhibitor_NN therapy_NN on_IN HRQOL_NNP ,_, as_IN those_DT
        medications_NNS were_VBD introduced_VBN during_IN the_DT period_NN the_DT HRQOL_NNP
        module_NN was_VBD used_VBN ._. Of_IN the_DT 2380_CD persons_NNS taking_VBG antiretroviral_NN
        medications_NNS at_IN the_DT time_NN of_IN interview_NN ,_, only_RB 39_CD (_( 1_CD ._. 6_CD %_NN )_)
        reported_VBD taking_VBG protease_NN inhibitors_NNS ._. Although_IN other_JJ studies_NNS
        have_VBP also_RB reported_VBN that_IN questions_NNS adapted_VBN from_IN the_DT MOS_NNP
        discriminated_JJ differences_NNS in_IN HRQOL_NNP among_IN populations_NNS with_IN
        HIV_NNP [_NN 15_CD 16_CD 17_CD 18_CD 19_CD ]_NN ,_, the_DT SHAS_NNP questionnaire_NN 's_POS shorter_JJR
        24_CD -_: item_NN subset_NN of_IN the_DT MOS_NNP questions_NNS may_MD limit_VB direct_JJ
        comparison_NN of_IN our_PRP$ results_NNS with_IN those_DT of_IN other_JJ studies_NNS ._.
        Still_RB ,_, our_PRP$ findings_NNS from_IN the_DT HRQOL_NNP analysis_NN in_IN SHAS_NNP
        generally_RB agree_VBP with_IN those_DT in_IN other_JJ published_VBN research_NN ._.
        Quality_NNP of_IN life_NN issues_NNS are_VBP also_RB important_JJ for_IN persons_NNS
        with_IN HIV_NNP as_IN they_PRP relate_VBP to_TO medication_NN adherence_NN ._. Complex_JJ
        medication_NN regimens_NNS and_CC side_NN effects_NNS can_MD affect_VB both_DT
        quality_NN of_IN life_NN and_CC adherence_NN [_NN 29_CD 30_CD 31_CD 32_CD ]_NN ._. Resistant_NNP
        viral_JJ strains_NNS may_MD emerge_VB when_WRB adherence_NN to_TO antiretroviral_NN
        regimens_NNS is_VBZ suboptimal_NN ._. After_IN the_DT initial_JJ HRQOL_NNP module_NN was_VBD
        used_VBN ,_, the_DT SHAS_NNP questionnaire_NN was_VBD modified_VBN to_TO include_VB
        questions_NNS on_IN use_NN of_IN past_JJ and_CC current_JJ medications_NNS (_( including_VBG
        protease_NN inhibitors_NNS )_) ,_, duration_NN of_IN current_JJ therapies_NNS ,_,
        measures_NNS of_IN adherence_NN ,_, and_CC reasons_NNS for_IN lack_NN of_IN adherence_NN ._.
        These_DT questions_NNS should_MD provide_VB valuable_JJ new_JJ data_NNS on_IN the_DT
        relationship_NN of_IN disease_NN progression_NN ,_, therapy_NN ,_, and_CC HRQOL_NNP
        among_IN participants_NNS in_IN the_DT SHAS_NNP Project_NNP ._.
      
      
        Conclusions_NNP
        The_DT evolution_NN toward_IN treatment_NN of_IN HIV_NNP disease_NN as_IN a_DT
        chronic_JJ illness_NN presents_VBZ additional_JJ challenges_NNS for_IN patients_NNS
        and_CC clinicians_NNS ._. Measures_NNS of_IN health-related_JJ quality_NN of_IN life_NN
        can_MD provide_VB important_JJ information_NN to_TO behavioral_JJ and_CC
        clinical_JJ studies_NNS of_IN antiretroviral_NN treatment_NN ,_, adherence_NN ,_,
        and_CC viral_JJ resistance_NN -_: factors_NNS that_WDT ultimately_RB influence_NN
        HIV-related_NNP morbidity_NN and_CC mortality_NN ._.
      
      
        Authors_NNP '_'' contributions_NNS
        MLC_NNP developed_VBD the_DT analysis_NN question_NN ,_, conducted_VBD the_DT data_NNS
        analysis_NN ,_, and_CC drafted_VBD the_DT manuscript_NN ._. AKN_NNP and_CC AJD_NNP
        participated_VBD in_IN developing_VBG the_DT analysis_NN question_NN ,_, and_CC have_VBP
        contributed_VBN to_TO and_CC approved_VBD the_DT final_JJ manuscript_NN ._.
      
    
  
